CN113195053B - 氨基酸化合物和使用方法 - Google Patents
氨基酸化合物和使用方法 Download PDFInfo
- Publication number
- CN113195053B CN113195053B CN201980066146.7A CN201980066146A CN113195053B CN 113195053 B CN113195053 B CN 113195053B CN 201980066146 A CN201980066146 A CN 201980066146A CN 113195053 B CN113195053 B CN 113195053B
- Authority
- CN
- China
- Prior art keywords
- tetrahydro
- naphthyridin
- homoserine
- ethyl
- cyclobutyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862742901P | 2018-10-08 | 2018-10-08 | |
| US62/742,901 | 2018-10-08 | ||
| PCT/US2019/055252 WO2020076862A1 (en) | 2018-10-08 | 2019-10-08 | Amino acid compounds and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113195053A CN113195053A (zh) | 2021-07-30 |
| CN113195053B true CN113195053B (zh) | 2024-08-30 |
Family
ID=70051340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980066146.7A Active CN113195053B (zh) | 2018-10-08 | 2019-10-08 | 氨基酸化合物和使用方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11180494B2 (enExample) |
| EP (1) | EP3863711A4 (enExample) |
| JP (1) | JP7523450B2 (enExample) |
| KR (1) | KR20210101205A (enExample) |
| CN (1) | CN113195053B (enExample) |
| AU (1) | AU2019358041A1 (enExample) |
| BR (1) | BR112021006620A2 (enExample) |
| CA (1) | CA3115643A1 (enExample) |
| CL (2) | CL2021000863A1 (enExample) |
| CO (1) | CO2021004279A2 (enExample) |
| CR (1) | CR20210224A (enExample) |
| CU (1) | CU24690B1 (enExample) |
| DO (1) | DOP2021000054A (enExample) |
| EA (1) | EA202190967A1 (enExample) |
| EC (1) | ECSP21032717A (enExample) |
| IL (1) | IL282026A (enExample) |
| JO (1) | JOP20210056A1 (enExample) |
| MX (1) | MX2021004015A (enExample) |
| PE (1) | PE20211463A1 (enExample) |
| PH (1) | PH12021550784A1 (enExample) |
| SG (1) | SG11202103283RA (enExample) |
| TW (1) | TW202028179A (enExample) |
| WO (1) | WO2020076862A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| EP4159727B1 (en) | 2017-02-28 | 2026-04-08 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| CU24684B1 (es) | 2018-03-07 | 2023-10-06 | Pliant Therapeutics Inc | Compuestos de aminoácidos como inhibidores de la integrina |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| PT3844162T (pt) | 2018-08-29 | 2025-03-28 | Morphic Therapeutic Inc | Inibidores da integrina alfa v beta6 |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| AU2019327475B2 (en) | 2018-08-29 | 2025-06-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| TW202028179A (zh) * | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| EP3952902A4 (en) | 2019-04-08 | 2022-12-21 | Pliant Therapeutics, Inc. | DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS |
| GB202010626D0 (en) | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
| TW202235417A (zh) | 2020-11-19 | 2022-09-16 | 美商普萊恩醫療公司 | 整合素抑制劑及其用途 |
| WO2024145245A2 (en) * | 2022-12-27 | 2024-07-04 | Pliant Therapeutics, Inc. | Alpha-v-beta-8 integrin inhibitors and uses thereof |
| GB202301024D0 (en) * | 2023-01-24 | 2023-03-08 | Univ Bradford | Compounds |
| CN122270455A (zh) * | 2023-12-22 | 2026-06-23 | 北京炫景瑞医药科技有限公司 | 一种靶向整合素αvβ6的配体、缀合物、组合物以及它们的用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018049068A1 (en) * | 2016-09-07 | 2018-03-15 | Pliant Therapeutics, Inc. | N-acyl amino acid compounds and methods of use |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| KR20100037600A (ko) | 2007-06-13 | 2010-04-09 | 브리스톨-마이어스 스큅 컴퍼니 | 응고 인자 억제제로서의 디펩티드 유사체 |
| US20120289481A1 (en) * | 2011-05-13 | 2012-11-15 | O'neil Jennifer | Compositions and methods for treating cancer |
| AU2014324426A1 (en) | 2013-09-30 | 2016-04-21 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| GB201417011D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| AU2016228852A1 (en) | 2015-03-10 | 2017-10-19 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| LT3275883T (lt) | 2015-03-25 | 2021-08-25 | Fujifilm Corporation | Naujo azotą turinčio junginio arba jo druskos gamybos būdas ir jo tarpinio junginio gamyba |
| KR20190026001A (ko) | 2016-07-05 | 2019-03-12 | 더 락커펠러 유니버시티 | 테트라하이드로나프티리딘펜탄아미드 인테그린 길항물질 |
| CN110167934B (zh) | 2016-11-08 | 2022-06-10 | 百时美施贵宝公司 | 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物 |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| EP4159727B1 (en) | 2017-02-28 | 2026-04-08 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| CU24684B1 (es) | 2018-03-07 | 2023-10-06 | Pliant Therapeutics Inc | Compuestos de aminoácidos como inhibidores de la integrina |
| US10538542B2 (en) | 2018-03-15 | 2020-01-21 | Pfizer Inc. | Cyclopentane-based modulators of STING (stimulator of interferon genes) |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| AU2019327475B2 (en) | 2018-08-29 | 2025-06-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| EP3843728B1 (en) | 2018-08-29 | 2025-04-30 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| TW202028179A (zh) * | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| EP3952902A4 (en) | 2019-04-08 | 2022-12-21 | Pliant Therapeutics, Inc. | DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS |
| KR20230049584A (ko) | 2020-05-07 | 2023-04-13 | 플라이언트 테라퓨틱스, 인크. | 아미노산 화합물을 사용한 호흡기 질환의 치료 |
-
2019
- 2019-10-07 TW TW108136254A patent/TW202028179A/zh unknown
- 2019-10-08 AU AU2019358041A patent/AU2019358041A1/en not_active Abandoned
- 2019-10-08 JP JP2021544112A patent/JP7523450B2/ja active Active
- 2019-10-08 SG SG11202103283RA patent/SG11202103283RA/en unknown
- 2019-10-08 CU CU2021000027A patent/CU24690B1/es unknown
- 2019-10-08 EP EP19870448.8A patent/EP3863711A4/en not_active Withdrawn
- 2019-10-08 MX MX2021004015A patent/MX2021004015A/es unknown
- 2019-10-08 CA CA3115643A patent/CA3115643A1/en active Pending
- 2019-10-08 JO JOP/2021/0056A patent/JOP20210056A1/ar unknown
- 2019-10-08 WO PCT/US2019/055252 patent/WO2020076862A1/en not_active Ceased
- 2019-10-08 PE PE2021000461A patent/PE20211463A1/es unknown
- 2019-10-08 EA EA202190967A patent/EA202190967A1/ru unknown
- 2019-10-08 BR BR112021006620A patent/BR112021006620A2/pt unknown
- 2019-10-08 CN CN201980066146.7A patent/CN113195053B/zh active Active
- 2019-10-08 CR CR20210224A patent/CR20210224A/es unknown
- 2019-10-08 US US16/596,649 patent/US11180494B2/en active Active
- 2019-10-08 KR KR1020217013781A patent/KR20210101205A/ko not_active Ceased
-
2021
- 2021-03-30 DO DO2021000054A patent/DOP2021000054A/es unknown
- 2021-04-04 IL IL282026A patent/IL282026A/en unknown
- 2021-04-07 CL CL2021000863A patent/CL2021000863A1/es unknown
- 2021-04-07 CO CONC2021/0004279A patent/CO2021004279A2/es unknown
- 2021-04-08 PH PH12021550784A patent/PH12021550784A1/en unknown
- 2021-05-07 EC ECSENADI202132717A patent/ECSP21032717A/es unknown
- 2021-10-18 US US17/504,384 patent/US11952376B2/en active Active
-
2023
- 2023-05-08 CL CL2023001331A patent/CL2023001331A1/es unknown
- 2023-12-19 US US18/545,952 patent/US20240270742A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018049068A1 (en) * | 2016-09-07 | 2018-03-15 | Pliant Therapeutics, Inc. | N-acyl amino acid compounds and methods of use |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3115643A1 (en) | 2020-04-16 |
| CO2021004279A2 (es) | 2021-04-30 |
| AU2019358041A1 (en) | 2021-05-20 |
| US11952376B2 (en) | 2024-04-09 |
| US20200109141A1 (en) | 2020-04-09 |
| CL2021000863A1 (es) | 2021-09-10 |
| PH12021550784A1 (en) | 2021-10-25 |
| US20220144829A1 (en) | 2022-05-12 |
| EP3863711A4 (en) | 2022-07-06 |
| EP3863711A1 (en) | 2021-08-18 |
| CN113195053A (zh) | 2021-07-30 |
| SG11202103283RA (en) | 2021-04-29 |
| DOP2021000054A (es) | 2021-08-31 |
| MX2021004015A (es) | 2021-06-23 |
| IL282026A (en) | 2021-05-31 |
| WO2020076862A1 (en) | 2020-04-16 |
| JOP20210056A1 (ar) | 2021-03-24 |
| CL2023001331A1 (es) | 2023-10-20 |
| ECSP21032717A (es) | 2021-06-30 |
| KR20210101205A (ko) | 2021-08-18 |
| CU20210027A7 (es) | 2021-11-04 |
| JP7523450B2 (ja) | 2024-07-26 |
| US20240270742A1 (en) | 2024-08-15 |
| BR112021006620A2 (pt) | 2021-07-06 |
| TW202028179A (zh) | 2020-08-01 |
| EA202190967A1 (ru) | 2021-09-17 |
| JP2022508657A (ja) | 2022-01-19 |
| PE20211463A1 (es) | 2021-08-05 |
| CR20210224A (es) | 2021-06-08 |
| US11180494B2 (en) | 2021-11-23 |
| CU24690B1 (es) | 2023-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7523450B2 (ja) | アミノ酸化合物およびその使用方法 | |
| CN110312719B (zh) | 作为jak家族激酶抑制剂的咪唑并吡咯并吡啶 | |
| JP6232429B2 (ja) | ＲＯＲγＴ阻害剤としての３−シクロヘキセニルおよびシクロヘキシル置換インドールおよびインダゾール化合物およびそれらの使用 | |
| JP4592077B2 (ja) | 嘔吐、抑鬱、不安および咳の処置のためのニューロキニン−１（ｎｋ−１）アンタゴニストとしての１−アミド−４−フェニル−４−ベンジルオキシメチル−ピペリジン誘導体および関連化合物 | |
| JP6530764B2 (ja) | ＲＯＲγ調節因子としてのピロリジニルスルホン誘導体およびその使用 | |
| CN112689507A (zh) | 具有无支链接头的氨基酸化合物及其使用方法 | |
| JP2026509001A (ja) | Ｅ．ｇ．癌を治療するためのｒａｓ－ｐｉ３ｋモジュレーターとしての１－（（［１，１’，－ビフェニル］－２－イル）スルホニル）－４－フルオロ－ｎ－（３－（メチルスルホニル）アリル）ピペリジン－４－カルボキサミド誘導体 | |
| CN105579444B (zh) | 哌啶基吲哚衍生物和它们作为补体因子b抑制剂的用途 | |
| RU2544011C2 (ru) | Триазолопиридины в качестве ингибиторов фосфодиэстеразы для лечения кожных заболеваний | |
| CN112135612A (zh) | 氨基酸化合物和使用方法 | |
| CA3042710A1 (en) | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as .alpha.v integrin inhibitors | |
| EP3484464A1 (en) | N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels | |
| KR20230035049A (ko) | 화합물, 조성물 및 방법 | |
| EP2976341A1 (en) | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | |
| CN107531679A (zh) | 芳香酰胺类衍生物、其制备方法及其在医药上的应用 | |
| AU2002305790B2 (en) | Chemical compounds and pharmaceutical compositions as cathepsin S inhibitors | |
| JP2021530532A (ja) | Ｔｒｋ阻害剤としてのイミダゾ［１，２−ｂ］ピリダジン誘導体 | |
| CN110278711A (zh) | 作为RORγ调节剂的三环砜 | |
| CN106928113B (zh) | 组织蛋白酶k抑制剂及其用途 | |
| HK40057175A (en) | Amino acid compounds and methods of use | |
| BR122023025996A2 (pt) | Compostos de aminoácidos, composição farmacêutica e kit compreendendo os mesmos, seus usos, e seu método de produção | |
| HK40105259A (en) | Diazepine derivatives useful in the treatment of clostridium difficile | |
| HK40049583A (en) | Amino acid compounds with unbranched linkers and methods of use | |
| JP2021514980A (ja) | 疼痛及び関連病態に対するピリジン−スルホンアミド化合物及びその使用 | |
| HK40008443A (en) | Imidazopyrrolopyridine as inhibitors of the jak family of kinases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40057175 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |